Eli Lilly & Co.

NYSE: LLY
$242.31
+$3.33 (+1.4%)
Closing price October 19, 2021
The March 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
These five top growth stocks could follow up on their first-quarter success with another victory for shareholders in the second quarter. They make sense for more aggressive growth accounts looking...
Some investors are looking for conservative growth ideas, and big pharma may be the ticket. These four top stocks have been hit hard, and the companies have paid dependable dividends for years.
The February 28 short interest data have been compared with the previous figures, and short interest in these top pharmaceutical stocks decreased.
The February 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
These five companies basically do all their business in the United States. They provide products or services that will be needed almost regardless of the severity or length of the coronavirus...
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and...
The January 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
24/7 Wall St. has put together a preview of the most prominent earnings reports this week, including Amazon.com, AT&T and General Electric.
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Dermira shares made a handy gain to close out the week after it was announced that Eli Lilly would be acquiring the firm.
The top analyst upgrades, downgrades and initiations for the final trading days of 2019 included Activision Blizzard, Amazon.com, Apple, Boeing, Eli Lilly, Johnson & Johnson, Lennar, Nio, Nvidia...
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The FDA has approved Allergan's treatment for migraines in adults. The drug is the first of its class to obtain FDA approval, but the new drug will compete with other recently released treatments for...